摘要
Saowapak PONGSASITORN 医师
皮肤科医师
Dual-Molecular PDLLA Injection for Full-Face Rejuvenation and Lifting
Objectives: 1. Understand the principles and characteristics of dual-molecular PDLLA biostimulators.
2. Learn a personalized injection technique using small and large PDLLA for full-face rejuvenation and lifting.
3. Apply targeted PDLLA injection mapping to address volume loss, skin laxity, and texture refinement.
Introduction: - This presentation proposes a structured, dual-molecular PDLLA injection protocol as a novel alternative to conventional fillers for full-face rejuvenation. By integrating small and large particle types across anatomical zones, the technique provides natural volumization, contour lifting, and skin refinement. With growing concern over filler-related complications, this method represents a forward-looking, safe, and reproducible injectable strategy in aesthetic medicine.
Materials / method: - Small-particle PDLLA was reconstituted with 5 cc normal saline and 1 cc Xylocaine (no adrenaline), injected into infraorbital and medial midface using fanning and bolus techniques in sub-dermal plane. Large-particle PDLLA was mixed with 7 cc normal saline and 1 cc Xylocaine, injected via fanning technique into temporal, zygomatic arch, preauricular, and jawline areas for volumization and lifting. Both used 25G cannula or 30G needle depending on area.
Results: - Visible facial lifting observed 1 month post-treatment with dual-molecular PDLLA. Brow elevation, jawline contour, and infraorbital hollowness improved. Skin showed enhanced firmness, refined texture, and reduced pore size. Rejuvenation effects were seen across treated areas. No major adverse events reported. Technique highlights the synergy of small and large PDLLA in layered facial biostimulation.
Conclusion: - This study supports the efficacy of dual-molecular PDLLA injection for full-face rejuvenation. Objective improvements were observed in brow elevation, jawline definition, pore size reduction, and skin texture at 1-month follow-up. No significant adverse events were reported. The protocol demonstrates a safe, anatomy-guided, and customizable approach with high patient satisfaction and minimal downtime.
披露 - Saowapak PONGSASITORN
> 您是否获得了任何资金来支持您关于这个主题的研究?
不是
> 您在这项研究工作中是否获得过任何酬金、报酬或其他形式的补偿?
不是
> 您是否与任何可能与您研究中涉及的药物、材料或器械存在激烈竞争的实体有任何财务关系?
不是
> 您是否拥有或已申请过与您研究中所讨论的仪器、药物或材料相关的任何专利?
不是
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
Published on 2025年 10月 7日 - Recorded during IMCAS China 2025